We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+31.61%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.19B
AUM Growth
+$204M
Cap. Flow
+$48.2M
Cap. Flow %
4.04%
Top 10 Hldgs %
41.65%
Holding
184
New
58
Increased
50
Reduced
24
Closed
34

Top Buys

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22.4M
2
FOLD
Amicus Therapeutics
FOLD
+$14.4M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$13.8M
4
BLUE
bluebird bio
BLUE
+$11.6M
5
RLYP
RELYPSA INC COM
RLYP
+$11.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.3M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
3
ARWR icon
Arrowhead Research
ARWR
+$18.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.7M
5
HCA icon
HCA Healthcare
HCA
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.07%
2 Financials 0.1%
3 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBM
126
DELISTED
Cambrex Corporation
CBM
$248K 0.02%
+11,488
New +$244K
CYBX
127
DELISTED
CYBERONICS INC
CYBX
$248K 0.02%
+4,454
New +$233K
EXAC
128
DELISTED
Exactech Inc
EXAC
$245K 0.02%
10,374
+5,910
+132% +$131K
PAHC icon
129
Phibro Animal Health
PAHC
$1.5B
$237K 0.02%
+7,526
New +$208K
BSTC
130
DELISTED
BioSpecifics Technologies Corp.
BSTC
$234K 0.02%
+6,065
New +$231K
PDLI
131
DELISTED
PDL BioPharma, Inc.
PDLI
$232K 0.02%
30,151
+19,968
+196% +$158K
CIVI
132
DELISTED
Civitas Solutions, Inc.
CIVI
$231K 0.02%
+13,585
New +$215K
AET
133
DELISTED
Aetna Inc
AET
$230K 0.02%
2,586
+1,278
+98% +$107K
CI icon
134
Cigna
CI
$78.4B
$228K 0.02%
+2,219
New +$219K
BCR
135
DELISTED
CR Bard Inc.
BCR
$228K 0.02%
+1,367
New +$221K
PRXL
136
DELISTED
Parexel International Corp
PRXL
$223K 0.02%
+4,005
New +$231K
USPH icon
137
US Physical Therapy
USPH
$1.22B
$216K 0.02%
+5,156
New +$203K
OXGN
138
DELISTED
OXIGENE INC COM
OXGN
$199K 0.02%
123,518
– –
SEM
139
DELISTED
Select Medical
SEM
$192K 0.02%
24,805
+8,071
+48% +$58.9K
LCI
140
DELISTED
Lannett Company, Inc.
LCI
$188K 0.02%
1,098
-32,544
-97% -$6.04M
SUPN icon
141
Supernus Pharmaceuticals
SUPN
$2.7B
$185K 0.02%
+22,285
New +$187K
NBSE
142
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$50K ﹤0.01%
+15
New +$46K
SGEN
143
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$29K ﹤0.01%
+900
New +$31.4K
XOMA
144
CALL
DELISTED
Xoma
XOMA
$1K ﹤0.01%
+10
New +$857
ICEL
145
DELISTED
CELLULAR DYNAMICS INTL INC COM STK (WI)
ICEL
$1K ﹤0.01%
164
– –
AMN icon
146
AMN Healthcare
AMN
$1.35B
– –
-7,855
Closed -$123K
ARCT icon
147
CALL
Arcturus Therapeutics
ARCT
$165M
– –
-76,714
Closed -$8.29M
ARCT icon
148
PUT
Arcturus Therapeutics
ARCT
$165M
– –
-69,571
Closed -$7.52M
ARWR icon
149
Arrowhead Research
ARWR
$12.1B
– –
-1,247,495
Closed -$18.4M
CRL icon
150
Charles River Laboratories
CRL
$11.3B
– –
-1,860
Closed -$111K
4 5
6
7 8

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Perceptive Advisors held 184 positions worth $1.19B, up 21% from $988M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Perceptive Advisors deployed $48.2M of net new capital in Q4 2014, opening 58 new positions and adding to 50 existing holdings. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was Celgene Corp, an estimated $24.3M trimmed.

  • Perceptive Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q4 2014, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q4 2014 reduction was Celgene Corp, cutting an estimated $24.3M.
  • Perceptive Advisors fully exited Arrowhead Research in Q4 2014, selling an estimated $18.4M.
  • Perceptive Advisors's ten largest holdings make up 42% of its $1.19B portfolio in Q4 2014.
  • Perceptive Advisors opened 58 new positions and closed 34 in Q4 2014.
  • Perceptive Advisors's portfolio value rose 21% quarter-over-quarter to $1.19B.

Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.